Sanofi-Aventis Canada Inc. v. Novopharm Limited, 2009 FC 1285 (Ramipril*)
Justice Snider - 2009-12-17
Read full decision. Automatically generated summary:
Sanofi-Aventis (Sanofi France), Sanofi-Aventis Canada Inc. (Sanofi Canada) and Sanofi-Aventis Deutschland GmbH (Sanofi Germany) (collectively Sanofi) have brought a motion to have three actions heard together with a common record. In each of the three actions, one or more of the Sanofi family of companies is named as Defendant. Each proceeding will require a calculation of damages under s. 8 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (NOC Regulations). A further common element is Canadian Patent No. 1,341,206 (the '206 Patent), a claim to the drug ramipril.
Decision relates to:
- T-1161-07 - SANOFI-AVENTIS CANADA INC. ET AL v. NOVOPHARM LIMITED
- T-1201-08 - SANOFI-AVENTIS CANADA INC. ET AL v. LABORATOIRE RIVA INC.
- T-1357-09 - APOTEX INC. v. SCHERING CORPORATION ET AL